Company intelligence / Profile preview

CureLab

Needham, Massachusetts, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

CureLab Oncology is a clinical-stage biotechnology company developing a novel class of DNA-based therapeutics and vaccines. The company's lead product, Elenagen, is a DNA plasmid encoding the p62/SQSTM1 protein, which functions as a master regulator of proteostasis, autophagy, and immune signaling. By targeting p62, CureLab aims to modulate the tumor microenvironment and chronic inflammation, potentially treating various cancers and age-related diseases. The company is currently conducting Phase 2 clinical trials for Elenagen in combination with standard-of-care treatments for solid tumors.

Therapeutic areas: OncologyImmunologyWomen's HealthMetabolic Disorders
Modalities: DNA vaccineGene therapy
Industry: Biotech

Beyond the preview

Go deeper on CureLab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CureLab.

Explore the full profile